Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Ferdinandos Skoulidis¹, Haniel A Araujo^#², Minh Truong Do^#², Yu Qian², Xin Sun², Ana Galan Cobo², John T Le², Meagan Montesion³, Rachael Palmer⁴, Nadine Jahchan⁴, Joseph M Juan⁵, Chengyin Min⁶, Yi Yu⁶, Xuewen Pan⁶, Kathryn C Arbour⁷, Natalie Vokes², Stephanie T Schmidt⁸, David Molkentine², Dwight H Owen⁹, Regan Memmott⁹, Pradnya D Patil¹⁰, Melina E Marmarelis¹¹, Mark M Awad¹², Joseph C Murray¹³, Jessica A Hellyer¹⁴, Justin F Gainor¹⁵, Anastasios Dimou¹⁶, Christine M Bestvina¹⁷, Catherine A Shu¹⁸, Jonathan W Riess¹⁹, Collin M Blakely²⁰, Chad V Pecot²¹, Laura Mezquita²², Fabrizio Tabbó²³, Matthias Scheffler²⁴, Subba Digumarthy²⁵, Meghan J Mooradian¹⁵, Adrian G Sacher²⁶, Sally C M Lau²⁷, Andreas N Saltos²⁸, Julia Rotow¹², Rocio Perez Johnson²⁹, Corinne Liu²⁹, Tyler Stewart³⁰, Sarah B Goldberg³¹, Jonathan Killam³², Zenta Walther³³, Kurt Schalper³³, Kurtis D Davies³⁴, Mark G Woodcock²¹, Valsamo Anagnostou¹³, Kristen A Marrone¹³, Patrick M Forde¹³, Biagio Ricciuti¹², Deepti Venkatraman¹², Eliezer M Van Allen¹², Amy L Cummings³⁵, Jonathan W Goldman³⁵, Hiram Shaish¹⁸, Melanie Kier³⁶, Sharyn Katz¹¹, Charu Aggarwal¹¹, Ying Ni¹⁰, Joseph T Azok¹⁰, Jeremy Segal³⁷, Lauren Ritterhouse³, Joel W Neal¹⁴, Ludovic Lacroix³⁸, Yasir Y Elamin², Marcelo V Negrao², Xiuning Le², Vincent K Lam¹³, Whitney E Lewis², Haley N Kemp², Brett Carter³⁹, Jack A Roth⁴⁰, Stephen Swisher⁴⁰, Richard Lee², Teng Zhou², Alissa Poteete², Yifan Kong², Tomohiro Takehara², Alvaro Guimaraes Paula², Edwin R Parra Cuentas⁴¹, Carmen Behrens⁴¹, Ignacio I Wistuba⁴¹, Jianjun Zhang², George R Blumenschein², Carl Gay², Lauren A Byers², Don L Gibbons², Anne Tsao², J Jack Lee⁴², Trever G Bivona²⁰, D Ross Camidge⁴³, Jhannelle E Gray²⁸, Natasha B Leighl²⁶, Benjamin Levy¹³, Julie R Brahmer¹³, Marina C Garassino¹⁷, David R Gandara¹⁹, Edward B Garon³⁵, Naiyer A Rizvi⁴⁴, Giorgio Vittorio Scagliotti⁴⁵, Jürgen Wolf²⁴, David Planchard³⁸, Benjamin Besse³⁸, Roy S Herbst³¹, Heather A Wakelee¹⁴, Nathan A Pennell¹⁰, Alice T Shaw⁴⁶, Pasi A Jänne¹², David P Carbone⁹, Matthew D Hellmann⁴⁷, Charles M Rudin⁷, Lee Albacker³, Helen Mann⁴⁸, Zhou Zhu⁴⁸, Zhongwu Lai⁴⁸, Ross Stewart⁴⁸, Solange Peters⁴⁹, Melissa L Johnson⁵⁰, Kwok K Wong⁵¹, Alan Huang⁶, Monte M Winslow^{5

14}, Michael J Rosen⁵, Ian P Winters⁵, Vassiliki A Papadimitrakopoulou⁵², Tina Cascone², Philip Jewsbury⁴⁸, John V Heymach⁵³

Affiliations

¹ Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. fskoulidis@mdanderson.org.
² Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Foundation Medicine, Cambridge, MA, USA.
⁴ Pionyr Immunotherapeutics, South San Francisco, CA, USA.
⁵ D2G Oncology, Mountain View, CA, USA.
⁶ Tango Therapeutics, Boston, MA, USA.
⁷ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁸ Department of Genomic Medicine and the Institute for Data Science in Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁹ Division of Medical Oncology, Ohio State University-James Comprehensive Cancer Center, Columbus, OH, USA.
¹⁰ Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
¹¹ Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
¹² Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
¹³ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
¹⁴ Department of Genetics, Stanford University, Stanford, CA, USA.
¹⁵ Massachussetts General Hospital, Boston, MA, USA.
¹⁶ Department of Oncology, Mayo Clinic, Rochester, MN, USA.
¹⁷ Department of Medicine, University of Chicago, Chicago, IL, USA.
¹⁸ Columbia University, New York, NY, USA.
¹⁹ University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
²⁰ University of California San Francisco, San Francisco, CA, USA.
²¹ UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
²² Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain.
²³ Ospedale Michele e Pietro Ferrero, Cuneo, Italy.
²⁴ Department of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
²⁵ Department of Radiology, Massachussetts General Hospital, Boston, MA, USA.
²⁶ Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
²⁷ Department of Medical Oncology, NYU Langone Perlmutter Cancer Center, New York, NY, USA.
²⁸ Department of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
²⁹ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³⁰ Division of Hematology-Oncology, University of California San Diego, La Jolla, CA, USA.
³¹ Yale School of Medicine, New Haven, CT, USA.
³² North Shore University Hospital, Manhasset, NY, USA.
³³ Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
³⁴ Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
³⁵ David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
³⁶ Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³⁷ Department of Pathology, University of Chicago, Chicago, USA.
³⁸ Institut Gustave Roussy, Villejuif, France.
³⁹ Department of Thoracic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴⁰ Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴¹ Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴² Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴³ University of Colorado Cancer Center, Denver, CO, USA.
⁴⁴ Synthekine, Menlo Park, CA, USA.
⁴⁵ University of Turin, Orbassano, Italy.
⁴⁶ Novartis Institute for Biomedical Research, Cambridge, MA, USA.
⁴⁷ AstraZeneca, Gaithersburg, MD, USA.
⁴⁸ AstraZeneca, Cambridge, UK.
⁴⁹ Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.
⁵⁰ Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA.
⁵¹ Division of Hematology & Medical Oncology, NYU Langone Perlmutter Cancer Center, New York, NY, USA.
⁵² Pfizer, New York, NY, USA.
⁵³ Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jheymach@mdanderson.org.

^# Contributed equally.

PMID: 40016449
PMCID: PMC11903295
DOI: 10.1038/s41586-025-08767-9

Published Erratum

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Ferdinandos Skoulidis et al. Nature. 2025 Mar.

. 2025 Mar;639(8054):E19.

doi: 10.1038/s41586-025-08767-9.

Authors

Affiliations

¹ Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. fskoulidis@mdanderson.org.
² Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Foundation Medicine, Cambridge, MA, USA.
⁴ Pionyr Immunotherapeutics, South San Francisco, CA, USA.
⁵ D2G Oncology, Mountain View, CA, USA.
⁶ Tango Therapeutics, Boston, MA, USA.
⁷ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁸ Department of Genomic Medicine and the Institute for Data Science in Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁹ Division of Medical Oncology, Ohio State University-James Comprehensive Cancer Center, Columbus, OH, USA.
¹⁰ Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
¹¹ Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
¹² Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
¹³ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
¹⁴ Department of Genetics, Stanford University, Stanford, CA, USA.
¹⁵ Massachussetts General Hospital, Boston, MA, USA.
¹⁶ Department of Oncology, Mayo Clinic, Rochester, MN, USA.
¹⁷ Department of Medicine, University of Chicago, Chicago, IL, USA.
¹⁸ Columbia University, New York, NY, USA.
¹⁹ University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
²⁰ University of California San Francisco, San Francisco, CA, USA.
²¹ UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
²² Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain.
²³ Ospedale Michele e Pietro Ferrero, Cuneo, Italy.
²⁴ Department of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
²⁵ Department of Radiology, Massachussetts General Hospital, Boston, MA, USA.
²⁶ Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
²⁷ Department of Medical Oncology, NYU Langone Perlmutter Cancer Center, New York, NY, USA.
²⁸ Department of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
²⁹ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³⁰ Division of Hematology-Oncology, University of California San Diego, La Jolla, CA, USA.
³¹ Yale School of Medicine, New Haven, CT, USA.
³² North Shore University Hospital, Manhasset, NY, USA.
³³ Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
³⁴ Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
³⁵ David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
³⁶ Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³⁷ Department of Pathology, University of Chicago, Chicago, USA.
³⁸ Institut Gustave Roussy, Villejuif, France.
³⁹ Department of Thoracic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴⁰ Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴¹ Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴² Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴³ University of Colorado Cancer Center, Denver, CO, USA.
⁴⁴ Synthekine, Menlo Park, CA, USA.
⁴⁵ University of Turin, Orbassano, Italy.
⁴⁶ Novartis Institute for Biomedical Research, Cambridge, MA, USA.
⁴⁷ AstraZeneca, Gaithersburg, MD, USA.
⁴⁸ AstraZeneca, Cambridge, UK.
⁴⁹ Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.
⁵⁰ Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA.
⁵¹ Division of Hematology & Medical Oncology, NYU Langone Perlmutter Cancer Center, New York, NY, USA.
⁵² Pfizer, New York, NY, USA.
⁵³ Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jheymach@mdanderson.org.

^# Contributed equally.

PMID: 40016449
PMCID: PMC11903295
DOI: 10.1038/s41586-025-08767-9

No abstract available

PubMed Disclaimer

Erratum for

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Galan-Cobo A, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP,… See abstract for full author list ➔ Skoulidis F, et al. Nature. 2024 Nov;635(8038):462-471. doi: 10.1038/s41586-024-07943-7. Epub 2024 Oct 9. Nature. 2024. PMID: 39385035 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- PubMed Central
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Affiliations

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Research Materials